ARTICLE | Company News
BHV Pharma, Kissei Pharmaceutical deal
January 10, 2011 8:00 AM UTC
BHV received exclusive rights outside of Japan, Korea and Taiwan to develop and commercialize Kissei's Remogliflozin etabonate. The selective sodium-glucose cotransporter 2 (SGLT2) inhibitor is in Ph...